📊 ANEB Key Takeaways
Is Anebulo Pharmaceuticals, Inc. (ANEB) a Good Investment?
Anebulo Pharmaceuticals is a pre-revenue pharmaceutical company with significant ongoing losses and negative cash flow, indicating it is in early-stage development without commercial operations. The company's financial viability depends entirely on successful drug development and future revenue generation, with current burn rate consuming approximately 29% of cash reserves annually.
Anebulo Pharmaceuticals remains a pre-revenue biotech with persistent operating and net losses, weak returns on capital, and negative free cash flow, so the core fundamental profile is still highly speculative. Its balance sheet is a meaningful offset, with cash representing most of total assets, very strong liquidity, and no long-term debt, but the business currently depends on continued cash consumption rather than proven commercial economics.
Why Buy Anebulo Pharmaceuticals, Inc. Stock? ANEB Key Strengths
- Strong liquidity position with $9.0M cash representing 95.7% of total assets
- Minimal debt burden with zero long-term debt and low liabilities ($1.5M)
- Excellent current/quick ratios (31.63x) providing substantial runway for operations
- Very strong liquidity, with $9.04M of cash and current and quick ratios of 31.63x
- Debt-free balance sheet reduces financial distress risk and limits fixed financing obligations
- Net loss and diluted EPS improved year over year, indicating some cost discipline or lower loss intensity
ANEB Stock Risks: Anebulo Pharmaceuticals, Inc. Investment Risks
- No revenue generation indicating company has not achieved commercialization of any products
- Persistent operating losses of $4.9M with negative net income of $4.2M
- Negative free cash flow of $2.6M annually creating material runway depletion risk; at current burn rate, cash reserves depleted in approximately 3.5 years without additional funding
- Extreme negative ROE (-52.4%) and ROA (-44.1%) demonstrating value destruction
- Zero insider transactions in last 90 days suggesting lack of management confidence or activity
- High execution risk inherent to pharmaceutical development stage companies with binary outcomes
- No revenue base, so growth quality and commercial viability are still unproven
- Negative operating income, net income, operating cash flow, ROE, and ROA show an unsustainable standalone earnings profile
- Cash burn remains material relative to equity and cash reserves, creating future financing risk if development timelines slip
Key Metrics to Watch
- Operating cash burn rate and cash runway duration
- Clinical trial progress and regulatory milestones for pipeline programs
- Equity financing activities and capital raise announcements
- Path to revenue generation and product commercialization timeline
- Changes in insider ownership and executive compensation structure
- Quarterly operating cash burn relative to cash balance
- Evidence of revenue generation or sustained narrowing of operating losses
Anebulo Pharmaceuticals, Inc. (ANEB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 31.63x current ratio provides a solid financial cushion.
ANEB Profit Margin, ROE & Profitability Analysis
ANEB vs Healthcare Sector: How Anebulo Pharmaceuticals, Inc. Compares
How Anebulo Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Anebulo Pharmaceuticals, Inc. Stock Overvalued? ANEB Valuation Analysis 2026
Based on fundamental analysis, Anebulo Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Anebulo Pharmaceuticals, Inc. Balance Sheet: ANEB Debt, Cash & Liquidity
ANEB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Anebulo Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.32 indicates the company is currently unprofitable.
ANEB Revenue Growth, EPS Growth & YoY Performance
Anebulo Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
ANEB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Anebulo Pharmaceuticals, Inc. (CIK: 0001815974)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ANEB
What is the AI rating for ANEB?
Anebulo Pharmaceuticals, Inc. (ANEB) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ANEB's key strengths?
Claude: Strong liquidity position with $9.0M cash representing 95.7% of total assets. Minimal debt burden with zero long-term debt and low liabilities ($1.5M). ChatGPT: Very strong liquidity, with $9.04M of cash and current and quick ratios of 31.63x. Debt-free balance sheet reduces financial distress risk and limits fixed financing obligations.
What are the risks of investing in ANEB?
Claude: No revenue generation indicating company has not achieved commercialization of any products. Persistent operating losses of $4.9M with negative net income of $4.2M. ChatGPT: No revenue base, so growth quality and commercial viability are still unproven. Negative operating income, net income, operating cash flow, ROE, and ROA show an unsustainable standalone earnings profile.
What is ANEB's revenue and growth?
Anebulo Pharmaceuticals, Inc. reported revenue of N/A.
Does ANEB pay dividends?
Anebulo Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find ANEB SEC filings?
Official SEC filings for Anebulo Pharmaceuticals, Inc. (CIK: 0001815974) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ANEB's EPS?
Anebulo Pharmaceuticals, Inc. has a diluted EPS of $-0.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ANEB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Anebulo Pharmaceuticals, Inc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ANEB stock overvalued or undervalued?
Valuation metrics for ANEB: ROE of -52.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ANEB stock in 2026?
Our dual AI analysis gives Anebulo Pharmaceuticals, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ANEB's free cash flow?
Anebulo Pharmaceuticals, Inc.'s operating cash flow is $-2.6M, with capital expenditures of N/A.
How does ANEB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -52.4% (avg: 15%), current ratio 31.63 (avg: 2).